+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Blood Cancer Drugs Global Market Report 2022, Blood Cancer Type, Drugs, Treatment Approaches

  • PDF Icon

    Report

  • 175 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5559819
Blood Cancer Drugs Global Market Report 2022 provides strategists, marketers and senior management with the critical information they need to assess the global blood cancer drugs market as it emerges from the Covid 19 shut down.



Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the blood cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Blood Cancer Drugs Market Global Report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope


Markets Covered:
1) By Blood Cancer Type: Leukemia; Lymphoma
2) By Drugs: Rituaxan/Mabthera (Rituximab); Gleevac/Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Others
3) By Treatment Approaches: Key Findings; Chemotherapeutic; mAbs/Targeted Therapies; Immunotherapeutic

Companies Mentioned: Amgen Inc.; AstraZeneca PLC.; Bayer AG; Celgene Corporation; Eli Lilly

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Blood Cancer Drugs Market

What is the estimated value of the Global Blood Cancer Drugs Market?

The Global Blood Cancer Drugs Market was estimated to be valued at $61.26 billion in 2022.

What is the growth rate of the Global Blood Cancer Drugs Market?

The growth rate of the Global Blood Cancer Drugs Market is 10.0%, with an estimated value of $89.75 billion by 2026.

What is the forecasted size of the Global Blood Cancer Drugs Market?

The Global Blood Cancer Drugs Market is estimated to be worth $89.75 billion by 2026.

Who are the key companies in the Global Blood Cancer Drugs Market?

Key companies in the Global Blood Cancer Drugs Market include Amgen Inc., AstraZeneca PLC., Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc. and Takeda Pharmaceutical Company Ltd..

Table of Contents

1. Executive Summary2. Blood Cancer Drugs Market Characteristics3. Blood Cancer Drugs Market Trends And Strategies4. Impact Of COVID-19 On Blood Cancer Drugs
5. Blood Cancer Drugs Market Size And Growth
5.1. Global Blood Cancer Drugs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Blood Cancer Drugs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Blood Cancer Drugs Market Segmentation
6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Leukemia
  • Lymphoma
6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Rituaxan/Mabthera (Rituximab)
  • Gleevac/Glivec (Imatinib)
  • Revlimid (Lenalidomide)
  • Velcade (Bortezomib)
  • Tasigna (Nilotinib)
  • Pomalyst (Pomalidomide)
  • Vidaza (Azacitidine)
  • Kyprolis (Carfilzomib)
  • Adcetris (Brentuximab Vedotin)
  • Others
6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Key Findings
  • Chemotherapeutic
  • mAbs/Targeted Therapies
  • Immunotherapeutic

7. Blood Cancer Drugs Market Regional And Country Analysis
7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Blood Cancer Drugs Market
8.1. Asia-Pacific Blood Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8.3. Asia-Pacific Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Blood Cancer Drugs Market
9.1. China Blood Cancer Drugs Market Overview
9.2. China Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
9.3. China Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Blood Cancer Drugs Market
10.1. India Blood Cancer Drugs Market, Segmentation By Blood Cancer Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
10.2. India Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Blood Cancer Drugs Market
11.1. Japan Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11.2. Japan Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Blood Cancer Drugs Market
12.1. Australia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12.2. Australia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Blood Cancer Drugs Market
13.1. Indonesia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13.2. Indonesia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Blood Cancer Drugs Market
14.1. South Korea Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14.2. South Korea Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Blood Cancer Drugs Market
15.1. Western Europe Blood Cancer Drugs Market Overview
15.2. Western Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15.3. Western Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Blood Cancer Drugs Market
16.1. UK Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16.2. UK Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Blood Cancer Drugs Market
17.1. Germany Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17.2. Germany Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Blood Cancer Drugs Market
18.4. France Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18.5. France Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Blood Cancer Drugs Market
19.1. Eastern Europe Blood Cancer Drugs Market Overview
19.2. Eastern Europe Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19.3. Eastern Europe Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Blood Cancer Drugs Market
20.1. Russia Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20.2. Russia Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Blood Cancer Drugs Market
21.1. North America Blood Cancer Drugs Market Overview
21.2. North America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21.3. North America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Blood Cancer Drugs Market
22.1. USA Blood Cancer Drugs Market Overview
22.2. USA Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22.3. USA Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Blood Cancer Drugs Market
23.1. South America Blood Cancer Drugs Market Overview
23.2. South America Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23.3. South America Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Blood Cancer Drugs Market
24.1. Brazil Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24.2. Brazil Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Blood Cancer Drugs Market
25.1. Middle East Blood Cancer Drugs Market Overview
25.2. Middle East Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25.3. Middle East Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Blood Cancer Drugs Market
26.1. Africa Blood Cancer Drugs Market Overview
26.2. Africa Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26.3. Africa Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Blood Cancer Drugs Market Competitive Landscape And Company Profiles
27.1. Blood Cancer Drugs Market Competitive Landscape
27.2. Blood Cancer Drugs Market Company Profiles
27.2.1. Amgen Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. AstraZeneca PLC
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Bayer AG
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Celgene Corporation
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Eli Lilly
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Blood Cancer Drugs Pipeline Analysis29. Key Mergers And Acquisitions In The Blood Cancer Drugs Market30. Blood Cancer Drugs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd.

The global blood cancer drugs market is expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a compound annual growth rate (CAGR) of 11.7%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $89.75 billion in 2026 at a CAGR of 10.0%.

The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukaemia, lymphoma, and myeloma.

The main types of blood cancer drugs are leukemia, and lymphoma. Leukemia is a blood-forming tissue cancer that affects the bone marrow and lymphatic tract. The different types of drugs include rituaxan/mabthera (rituximab), gleevac/glivec (imatinib), revlimid (lenalidomide), velcade (bortezomib), tasigna (nilotinib), pomalyst (pomalidomide), vidaza (azacitidine), kyprolis (carfilzomib), adcetris (brentuximab vedotin), others and involve various treatment approaches such as key findings, chemotherapeutic, mabs/targeted therapies, immunotherapeutic.

North America is the largest region in the blood cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukaemia, and 275,047 cases myeloma. Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukaemia in the United States and 68,000 deaths resulted from blood cancer. According to national cancer institute, the deaths due to blood cancer reached around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.

Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments. According to Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.

Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels. This technology helps to analyse large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs. Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development. For instance, Johnson and Johnson entered into an agreement with BenevolentAI, a UK-based artificial intelligence company (start-up), to mine data for designing new blood cancer drugs.

The Food and Drug Administration (FDA) is a federal agency regulating the blood cancer drugs market. In June 2019, FDA declined to approve Daiichi Sankyo’s leukaemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer. The rejection of drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval.

In 2019, Eli Lilly, a US-based pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers. The company focuses on building small molecule cancer drugs for genetically defined cancer patients. The company was founded in 2013 and is headquartered in Stamford, Connecticut, USA.

The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen Inc.
  • AstraZeneca PLC.
  • Bayer AG
  • Celgene Corporation
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • Pfizer Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Ltd.
  • F.Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Astellas Pharma Inc.
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • Merck and Company
  • Roche Holding AG

Methodology

Loading
LOADING...